NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.